DC 欄位 | 值 | 語言 |
dc.contributor | 臺大醫院;臺大醫院-小兒部;臺大醫院雲林分院;臺大醫院-醫學研究部; | en |
dc.contributor.author | Chiu, Hsin-Hui | en |
dc.contributor.author | Wu, Mei-Hwan | en |
dc.contributor.author | Wang, Jou-Kou | en |
dc.contributor.author | Lu, Chun-Wei | en |
dc.contributor.author | Chiu, Shuenn-Nan | en |
dc.contributor.author | Chen, Chun-An | en |
dc.contributor.author | Lin, Ming-Tai | en |
dc.contributor.author | Hu, Fu-Chang | en |
dc.creator | Chiu, Hsin-Hui;Wu, Mei-Hwan;Wang, Jou-Kou;Lu, Chun-Wei;Chiu, Shuenn-Nan;Chen, Chun-An;Lin, Ming-Tai;Hu, Fu-Chang | en |
dc.creator | 胡賦強 ;邱馨慧 | zh-tw |
dc.date | 2013 | en |
dc.date.accessioned | 2014-02-14T09:55:16Z | - |
dc.date.accessioned | 2018-07-11T18:37:24Z | - |
dc.date.available | 2014-02-14T09:55:16Z | - |
dc.date.available | 2018-07-11T18:37:24Z | - |
dc.date.issued | 2013 | - |
dc.identifier.uri | http://ntur.lib.ntu.edu.tw//handle/246246/259860 | - |
dc.description.abstract | Objective: To assess the tolerability and efficacy of the investigational use of the angiotensin II receptor blocker losartan added to beta-blockade (BB) to prevent progressive aortic root dilation in patients with Marfan syndrome (MFS).
Patients and Methods: Between May 1, 2007, and September 31, 2011, 28 patients with MFS (11 males [39%]; mean +/- SD age, 13.1 +/- 6.3 years) with recognized aortic root dilation (z score > 2.0) and receiving BB (atenolol or propranolol) treatment were enrolled. They were randomized to receive BB (BB: 13 patients) or beta-blockade and losartan (BB-L: 15 patients) for 35 months.
Results: In the BB-L group, aortic root dilation was reduced with treatment, and the annual dilation rate of the aortic root was significantly lower than that of the BB group (0.10 mm/yr vs 0.89 mm/yr; P=.02). The absolute aortic diameters at the sinus of Valsalva, annulus, and sinotubular junction showed similar trends, with a reduced rate of dilation in the BB-L group (P=.02, P=.03, and P=.03, respectively). Five patients (33%) treated with BB-L were noted to have a reduced aortic root diameter. However, the differences between the groups regarding changes in aortic stiffness and cross-sectional compliance were not statistically significant.
Conclusion: This randomized, open-label, active controlled trial mostly based on a pediatric population demonstrated for the first time that losartan add-on BB therapy is safe and provides more effective protection to slow the progression of aortic root dilation than does BB treatment alone in patients with MFS. Trial Registration: clinicaltrials.gov Identifier: NCT00651235. (C) 2013 Mayo Foundation for Medical Education and Research square Mayo Clin Proc. 2013; 88(3): 271-276 | en |
dc.format.extent | 110 bytes | - |
dc.format.mimetype | text/html | - |
dc.language | en-us | en |
dc.relation | Mayo Clin. Proc., 88(3), 271-276 | en |
dc.relation.ispartof | Mayo Clin. Proc. | - |
dc.title | Losartan Added to beta-Blockade Therapy for Aortic Root Dilation in Marfan Syndrome: A Randomized, Open-Label Pilot Study | en |
dc.relation.pages | 271-276 | - |
dc.relation.journalvolume | 88 | - |
dc.relation.journalissue | 3 | - |
dc.identifier.uri.fulltext | http://ntur.lib.ntu.edu.tw/bitstream/246246/259860/1/index.html | - |
item.fulltext | with fulltext | - |
item.grantfulltext | open | - |
顯示於: | 醫學系
|